A case study from the ROSELA trial demonstrates that the relacorilant regimen can induce profound and lasting responses. A patient with difficult-to-treat platinum-resistant disease achieved a complete response that was maintained for 22 cycles and persisted even after treatment cessation, a rare and clinically significant outcome for this patient population.

Subgroup analysis of the ROSELLA trial shows a consistent overall survival benefit for the relacorilant-nab-paclitaxel combination, even in patients with a short interval (<6 months) since their last taxane exposure. This crucial finding supports using the regimen as a taxane re-challenge without concern for diminished efficacy.

The persistent separation of survival curves in the ROSELLA trial suggests relacorilant's benefit extends beyond sensitizing tumors to chemotherapy. By acting as a glucocorticoid receptor antagonist and blocking immunosuppressive cortisol, it may also have a favorable immune-modulatory effect.

A consistent pattern has emerged across new trials in platinum-resistant ovarian cancer (ROSELLA, KEYNOTE-B96, MIRASOL): therapies provide only modest progression-free survival (PFS) but a more substantial overall survival (OS) advantage, suggesting a shared biological effect.

The addition of relacorilant to nab-paclitaxel offers a new standard of care for platinum-resistant ovarian cancer that benefits a broad patient population. Unlike many modern targeted therapies, its efficacy does not depend on a specific biomarker, simplifying patient selection and broadening its applicability in clinical practice.

After a decade with no new therapies improving survival, the landscape for platinum-resistant ovarian cancer is transforming. The recent successes of mirvetuximab, the pembrolizumab/paclitaxel combo, and relacorilant/nab-paclitaxel have all demonstrated statistically significant overall survival benefits, heralding a new era of effective options.

The glucocorticoid receptor antagonist relacorilant does not require biomarker testing for patient selection. Its target is ubiquitously expressed in over 95% of ovarian cancer tissues, making it a broadly applicable therapy without the need for additional screening.

A Phase 2 trial found that administering the GR antagonist relacorilant intermittently (day before, of, and after chemo) was less toxic than continuous daily dosing. This intermittent schedule showed fewer grade 3 adverse events but still delivered significant improvements in progression-free and overall survival, informing the successful Phase 3 study design.

Recent trials for platinum-resistant ovarian cancer, including ROSELLA (relacorilant), show a pattern of small (e.g., one month) progression-free survival gains but much larger (e.g., four months) overall survival benefits. This suggests these therapies may positively influence the long-term disease course or response to subsequent treatments.